Digirad gears up for nSPEED trial:
This article was originally published in Clinica
Executive Summary
Gamma camera manufacturer Digirad is gearing up to start multicentre trials of its nSPEED technology - an advanced 3D SPECT image reconstruction technique. During the trial, the company hopes to show that nSPEED can cut acquisition time for cardiac SPECT in half, while maintaining clinical results equivalent to or better than 2D reconstruction techniques. The firm said it is currently "striving" to obtain acceptance from the American Society of Nuclear Cardiology and other societies in order to meet accreditation requirements for the product. nSPEED models depth-dependent point response function in an iterative reconstruction algorithm (OSEM), enabling depth-dependent resolution recovery and improving chamber contrast in SPECT images.
You may also be interested in...
US FDA Drugs Center Ready To Break Down Silos On Regulatory Innovation
CDER Director Cavazzoni is promising to increase coordination and collaboration to accelerate broader adoption of innovative clinical trial designs and other approaches to speed drug development. A new "Quantitative Medicine Center of Excellence" illustrates the approach.
New OSP Director To Guide CDER-Wide IT Upgrades; System Enhancements Speed ANDA Assessments
Generic Drug Structured Assessment for Bioequivalence launched in 2023 and has been used in 40 ANDA reviews so far.
New EU Approvals
The Pink Sheet's list of EU centralized approvals of new active substances has been updated to add two new products, including Ryzneuta, Evive Biotechnology's treatment for chemotherapy-induced neutropenia.